(4R,5R,6S)-6-(1-hydroxyethyl)-3-[(3S,5S)-5-[(1R)-1-hydroxy-3-methylamino-propyl]pyrrolidin-3-yl]sulf


CAS No. : 149951-16-6

(4R,5R,6S)-6-(1-hydroxyethyl)-3-[(3S,5S)-5-[(1R)-1-hydroxy-3-methylamino-propyl]pyrrolidin-3-yl]sulf,149951-16-6
Product Details
Cat No:M098211
Molecular Formula:C18H29N3O5S
Molecular Weight:399.506
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Appearance:Solid powder
Purity: > 98%
Cat No:M098211
Cas No:149951-16-6
Product-Name:(4R,5R,6S)-6-(1-hydroxyethyl)-3-[(3S,5S)-5-[(1R)-1-hydroxy-3-methylamino-propyl]pyrrolidin-3-yl]sulf
IUPAC Name:(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[(3S,5S)-5-[(1R)-1-hydroxy-3-(methylamino)propyl]pyrrolidin-3-yl]sulfanyl-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
InChI:InChI=1S/C18H29N3O5S/c1-8-14-13(9(2)22)17(24)21(14)15(18(25)26)16(8)27-10-6-11(20-7-10)12(23)4-5-19-3/h8-14,19-20,22-23H,4-7H2,1-3H3,(H,25,26)/t8-,9-,10+,11+,12-,13-,14-/m1/s1
InChIKey:PZLOCBSBEUDCPF-YJIVIRPOSA-N
SMILES:CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(CCNC)O)C(=O)O)C(C)O
Lenapenem, also known as carbapenem, is a broad-spectrum, carbapenem antibiotic with bactericidal activity. Lenapenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. This inhibition weakens the bacterial cell wall and leads to lytic cell death in a wide range of Gram-positive and Gram-negative aerobic and anaerobic pathogens

1: Breilh D, Texier-Maugein J, Allaouchiche B, Saux MC, Boselli E. Carbapenems. J Chemother. 2013 Feb;25(1):1-17. doi: 10.1179/1973947812Y.0000000032. Review. PubMed PMID: 23433439.
2: Rafailidis PI, Falagas ME. Options for treating carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2014 Dec;27(6):479-83. doi: 10.1097/QCO.0000000000000109. Review. PubMed PMID: 25259809.
3: Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. 2014 Aug;74(12):1315-33. doi: 10.1007/s40265-014-0267-8. Review. PubMed PMID: 25091170; PubMed Central PMCID: PMC4258832.
4: Pacifici GM, Allegaert K. Clinical pharmacology of carbapenems in neonates. J Chemother. 2014 Apr;26(2):67-73. doi: 10.1179/1973947813Y.0000000110. Epub 2013 Dec 6. Review. PubMed PMID: 24090536.
5: Temkin E, Adler A, Lerner A, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. Ann N Y Acad Sci. 2014 Sep;1323:22-42. doi: 10.1111/nyas.12537. Review. PubMed PMID: 25195939.
6: Kula B, Djordjevic G, Robinson JL. A systematic review: can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins? Clin Infect Dis. 2014 Oct 15;59(8):1113-22. doi: 10.1093/cid/ciu587. Epub 2014 Jul 21. Review. Erratum in: Clin Infect Dis. 2015 Jan 1;60(1):175. Clin Infect Dis. 2015 Jan 1;60(1):175. PubMed PMID: 25048853.
7: Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60. doi: 10.1128/AAC.00296-11. Epub 2011 Aug 22. Review. PubMed PMID: 21859938; PubMed Central PMCID: PMC3195018.
8: Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012 May;18(5):263-72. doi: 10.1016/j.molmed.2012.03.003. Epub 2012 Apr 3. Review. PubMed PMID: 22480775.
9: Perez F, Van Duin D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleve Clin J Med. 2013 Apr;80(4):225-33. doi: 10.3949/ccjm.80a.12182. Review. PubMed PMID: 23547093; PubMed Central PMCID: PMC3960994.
10: Yamamoto M, Pop-Vicas AE. Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have? Crit Care. 2014 Jun 27;18(3):229. doi: 10.1186/cc13949. Review. PubMed PMID: 25041592; PubMed Central PMCID: PMC4075344.
11: Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. Open Forum Infect Dis. 2015 May 5;2(2):ofv050. doi: 10.1093/ofid/ofv050. eCollection 2015 May 5. Review. PubMed PMID: 26125030; PubMed Central PMCID: PMC4462593.
12: Nicolau DP, Carmeli Y, Crank CW, Goff DA, Graber CJ, Lima AL, Goldstein EJ. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents. 2012 Jan;39(1):11-5. doi: 10.1016/j.ijantimicag.2011.08.018. Epub 2011 Nov 1. Review. PubMed PMID: 22047702.
13: Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther. 2013 Feb;11(2):159-77. doi: 10.1586/eri.12.162. Review. PubMed PMID: 23409822.
14: Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012 Dec;67(12):2793-803. doi: 10.1093/jac/dks301. Epub 2012 Aug 21. Review. PubMed PMID: 22915465.
15: Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, Mussini C, Leibovici L. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014 Sep;69(9):2305-9. doi: 10.1093/jac/dku168. Epub 2014 May 28. Review. PubMed PMID: 24872346.
16: van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013 Feb;75(2):115-20. doi: 10.1016/j.diagmicrobio.2012.11.009. Epub 2013 Jan 3. Review. PubMed PMID: 23290507; PubMed Central PMCID: PMC3947910.
17: Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paul M. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013 Oct;57(10):5104-11. doi: 10.1128/AAC.01230-13. Epub 2013 Aug 5. Review. PubMed PMID: 23917322; PubMed Central PMCID: PMC3811454.
18: Evans BA, Hamouda A, Amyes SG. The rise of carbapenem-resistant Acinetobacter baumannii. Curr Pharm Des. 2013;19(2):223-38. Review. PubMed PMID: 22894617.
19: Pogue JM, Mann T, Barber KE, Kaye KS. Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management. Expert Rev Anti Infect Ther. 2013 Apr;11(4):383-93. doi: 10.1586/eri.13.14. Review. PubMed PMID: 23566148.
20: Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013 Jan;56(2):272-82. doi: 10.1093/cid/cis857. Epub 2012 Oct 16. Review. PubMed PMID: 23074314.


Recommended Products
  • CAS No. :17017-83-3
    Product Name:

    potassium 2-(2,5-dihydroxy-4-octadecylphenyl)-2-methylpropanesulphonate

    Cat No: M078519 View details
  • CAS No. :16735-23-2
    Product Name:

    2-AMINO-3-HYDROXY-1-PHENYL-1-PROPANONE

    Cat No: M078520 View details
  • CAS No. :17938-06-6
    Product Name:

    1-NAPHTHYLTRIETHOXYSILANE

    Cat No: M078521 View details
  • CAS No. :16369-14-5
    Product Name:

    D/L-NORVALINOL

    Cat No: M078522 View details